Inhibition of Restenosis in Stented Porcine Coronary Arteries: Uptake of Paclitaxel from Angiographic Contrast Media

Investigative Radiology

Volumn 39, Issue 3, 2004, Pages 182-186

  Speck, Ulrich ^a,e   Scheller, Bruno ^b   Abramjuk, Claudia ^a   Grossmann, Stephan ^a   Mahnkopf, Dirk ^c   Simon, Oliver ^d  

^a HUMBOLDT UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c Institute of Medical Technology GmbH   (Germany)

^d Anakat GmbH   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Contrast media; Drug targeting; Paclitaxel; Restenosis

Indexed keywords

CONTRAST MEDIUM; IOPROMIDE; PACLITAXEL;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DOSE RESPONSE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRACORONARY INFUSION; LEFT CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; RIGHT CORONARY ARTERY; SWINE;

EID: 1342344632     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000116125.96544.64     Document Type: Article

References (15)

1. Duda St, Poerner TC, Wiesinger B, et al. Drug-eluting stents: potential applications for peripheral arterial occlusive disease. J Vasc Interv Radiol. 2003;14:291-301.
2. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part II. Circulation. 2002;106:2859-2866.
3. Park S-J, Shim WE, Ho DS. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
4. Gershlick AH. Treating atherosclerosis: local drug delivery from laboratory studies to clinical trials. Atherosclerosis. 2002;160:259-271.
5. Scheller B, Speck U, Romeike B, et al. Contrast media as a carrier for local drug delivery: Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart. 2003;24:1462-1467.
6. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003;42:1415-1420.
7. Scheller B, Speck U, Schmitt A, et al. Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting. Invest Radiol. 2002;37:29-34.
8. Brara PS, Moussavian M, Grise MA, et al. Pilot trial of oral rapamycin for recalcitrant restenosis. Circulation. 2003;107:1722-1724.
9. Nakatani M, Takeyama Y, Shibata M, et al. Mechanisms of restenosis after coronary intervention. Difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol. 2003;12:40-48.
10. Herdeg Ch, Oberhoff M, Baumbach A, et al. Visualization and comparison of drug effects after local paclitaxel delivery with different catheter types. Basic Res Cardiol. 1999;94:454-463.
11. Van Zuylen L, Karlsson MO, Verweij J, et al. Pharmacokinetic modeling of paclitaxel encapsulation in cremophor EL micelles. Cancer Chemother Pharmacol. 2001;47:309-318.
12. Malingré MM, Schellens JHM, Van Tellingen O, et al. The co-solvent cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer. 2001;85:1472-1477.
13. Oberhoff M, Herdeg C, Ghobainy RA, et al. Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Cathet Cardiovasc Intervent. 2001;53:562-568.
14. Clauss W, Scheller B, Schmitt A, et al. No difference between modern contrast media in neointimal proliferation and restenosis following coronary stenting in pigs. Invest Radiol. 2003;38:743-749.
15. Mross K, Holländer N, Hauns B, et al. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol. 2000;45:463-470.